Cite
MLA Citation
W. Yu et al.. “P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.” HemaSphere, vol. 6, n.d., pp. 490–491. http://access.bl.uk/ark:/81055/vdc_100159756984.0x00001a